ArticleBMC surgery2025
Predictors of postoperative recurrence of pheochromocytoma: a monocentric study.
Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Resolution of reverse takotsubo cardiomyopathy secondary to presumed pheochromocytoma with intralesional hemorrhage.JCEM case reports · 2026Article
- Peritoneal implantation of pheochromocytoma - pheochromocytomatosis: a case report and mini review.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo discuss the risk factors affecting the recurrence of pheochromocytoma (PCC) following surgery.
methodsWe retrospectively reviewed patients who were hospitalized and underwent surgery for PCC between January 2012 and December 2020 at Chinese People's Liberation Army (PLA) General Hospital. Inclusion criteria were pathological diagnosis of PCC and availability of follow up.
resultsIn total, 451 patients met the inclusion criteria. The average age was 45.89 years, and the median tumor diameter was 5.75 cm. The mean recurrence time was 34.24 months. Of the 451 patients receiving surgery, there were 35 recurrent cases (7.85%). The univariate test showed that age, hypertension, history of PCC recurrence, Ki-67 index ≥ 5, bilateral tumor, duration of phenazopyridine administration, DBP at admission, open operation, intraoperative HR minimum, the number of episodes of intraoperative HR over 120 bpm, the number of episodes of intraoperative hemodynamic instability, and intraoperative bleeding were associated with recurrence after surgery. Multivariate COX regression analysis of age (hazard ratio 0.95), hypertension (hazard ratio 7.14), history of PCC recurrence (hazard ratio 69.35), family history of hypertension (hazard ratio 16.30), bilateral tumor (hazard ratio 7.38), tumor size (hazard ratio 1.05), the number of episodes of hemodynamic instability (hazard ratio 114.91) and duration of intraoperative instability (hazard ratio 1.12) were the independent risk factors on recurrence following surgery.
conclusionsAge, hypertension, history of PCC recurrence, family history of hypertension, bilateral tumor, tumor size, the number of episodes and the duration of intraoperative hemodynamic instability were independent risk factors on recurrence following surgery. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.